Source of the article:MedRobotReprint Requirements: You can directly reprint, please credit the source at the beginning of the article.
Recently,TIROMU(hereinafter referred to as "TIROMU") announced the completionTens of Millions of RMB in Pre-A Round FinancingThis round of financing was jointly led by Aibohongsheng and Qihang Venture Capital, with Mingheng Meikang following up on the investment. Fenghe Capital served as the exclusive financial advisor.Public information shows that the funds from this round of financing will be mainly used to promoteClinical Trials and Registration Applications for Fundus Injection Surgical Robots, Accelerating the R&D Iteration of General Ophthalmic Surgical Robots, as well as the industrialization and commercialization of related technologies. The company did not disclose more detailed information such as the specific amount of financing, post-investment valuation, and the proportion of fund usage in this round.TIROMUThe company is positioned as a research and development enterprise for microsurgical robots, focusing onIntelligent Surgical Solutions for Ophthalmic DiseasesIts research and development focuses on key technical fields such as high-precision mechanical structures, micro-force feedback control, and intraoperative image fusion. Core team members come from universities like Tsinghua University and Waseda University in Japan, as well as medical robotics companies such as TIROMU, REMEBOT, and Meiya Medical, bringing industry backgrounds in robotic system development and clinical translation.In terms of product development, the company has launched a retinal injection surgical robot, which has entered the clinical trial stage. Meanwhile, a new generation of the product is currently under development, incorporating intraoperative imaging systems to achieve surgical path planning and navigation functions.# Main Products and TechnologiesAccording to the company's public information, its core products and technologies include:- Intravitreal Injection Surgical Robot: Adopting a 6-DOF mainstream architecture, with a rail-type RCM (Remote Center of Motion) structure, the execution accuracy can reach 2 microns, and it has entered the clinical trial stage.
- Surgical Robot 2.0 Version: The integration of OCT imaging in fusion procedures enables real-time automatic surgical path planning and navigation, which is expected to become an ophthalmic surgical robot with "autonomous driving" capabilities.
In terms of product planning, the company is starting with an ophthalmic microsurgical robot and simultaneously exploring the application of high-precision microscopic operation platforms in other microsurgical scenarios such as otolaryngology and neurosurgery. The related products are still in the research and development stage, and the specific product forms and market entry paths have not been disclosed.
According to MedRobot's query on the Qichacha website, the company's patent situation is as follows:
# MedRobot Content Index（Sorting(Regardless of order)Well-known surgical robot companies and upstream/downstream enterprises
